AbbVie Inc. reported net revenues of USD 16.62 billion for the fourth quarter (Q4) ended December 31, 2025. Net revenues in the U.S. reached USD 12.79 billion, while international net revenues totaled USD 3.82 billion. Compared to the same period in the previous year, total net revenues increased by 10 percent, with U.S. net revenues up 9 percent and international net revenues up 13.5 percent. During the quarter, AbbVie announced a voluntary agreement with the Trump administration aimed at advancing access and affordability for Americans and supporting pharmaceutical innovation in the United States. Under this three-year agreement, AbbVie will provide low prices in Medicaid and expand affordable, direct-to-patient offerings for widely used treatments. The company also committed USD 100 billion in U.S. research and development and capital investments, including manufacturing, over the next decade. The agreement grants AbbVie exemption from tariffs and future pricing mandates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief on February 04, 2026, and is solely responsible for the information contained therein.